Escitalopram

Limits on what this shows

• Key negative/null findings: Effects were concentration-dependent, reaching significance only at high double/triple-digit micromolar concentrations. Typical human therapeutic steady-state escitalopram plasma concentrations are on the order of tens to low hundreds of nanomol/L, roughly 250 to 2,000-fold below the concentrations tested here. No escitalopram-specific human mitochondrial-function study (platelet or tissue) was located.
• At-risk subgroups: None established in humans; this is an in vitro, non-clinical finding.
• Counter-evidence: See the Oxidative stress entry: a small human trial at clinical dosing found reduced, not worsened, systemic oxidative-stress markers after 6 weeks of escitalopram. A different endpoint, but it weighs against a clinically meaningful bioenergetic-harm signal at therapeutic exposure.

Regulatory status

Not addressed in the FDA label.

Population evidence / mechanism

Hroudová J, Fišar Z, Łupták M. 2023. Antioxidants 12(6):1208, doi:10.3390/antiox12061208. In vitro study on isolated pig brain mitochondria; escitalopram tested alongside fluvoxamine, sertraline, and paroxetine. At 100 µmol/L, escitalopram inhibited complex I activity to 43.9% of control and reduced complex II+III and complex IV activity. Escitalopram also acted as a full inhibitor of both MAO-A and MAO-B in this system.

Counter-evidence held on record

This is an in vitro, supraphysiologic-concentration finding in isolated animal mitochondria. Do not present as evidence of clinical mitochondrial toxicity at therapeutic human dosing; no such human data exist.

Limits on what this shows

• Key negative/null findings: GPx did not change significantly. Single small trial (n=18 per arm), not independently replicated.
• At-risk subgroups: Not established.
• Counter-evidence / competing explanation: Confounding by indication is presumed here per standard practice: elevated oxidative markers are a well-documented feature of the depressive state itself, so their normalization alongside clinical improvement does not by itself establish a direct drug-level antioxidant mechanism.

Regulatory status

Not addressed in the FDA label.

Population evidence

Çimen et al., Psychiatry and Clinical Psychopharmacology (Klinik Psikofarmakoloji Bülteni) 25(3):272-279, doi:10.5455/bcp.20150215102247. n=18 MDD patients (11 women, 7 men) and 18 healthy controls; patients received escitalopram 20 mg/day for 6 weeks. Before treatment, SOD, catalase (CAT), malondialdehyde (MDA), and nitric oxide (NO) were all significantly elevated in patients versus controls. After treatment, SOD, CAT, MDA, and NO were all significantly reduced; glutathione peroxidase (GPx) did not change significantly.

Mechanism

Not established. Proposed as more plausibly reflecting resolution of the depressive episode's own illness-associated oxidative burden than a direct pharmacological antioxidant effect of escitalopram; this is a competing explanation, not a settled mechanism.

Counter-evidence held on record

Do not present escitalopram as an antioxidant or oxidative-stress-reducing supplement equivalent. The finding is real but small, unreplicated, and plausibly reflects illness resolution rather than a direct pharmacological effect. It also should not be read as contradicting the separate, mechanism-level, high-concentration in vitro mitochondrial-inhibition finding above; the two rest on entirely independent sources and measure different things (see Overlap map).

Limits on what this shows

• Key negative/null findings: No study was located measuring serum iron, ferritin, or transferrin saturation in escitalopram-treated patients. This entry is a mechanism/outcome-adjacent extrapolation, not a measured nutrient finding.
• At-risk subgroups: Concurrent NSAID, aspirin, or anticoagulant use substantially raises class-level GI bleeding risk (a well-documented interaction in its own right, though not iron-specific).
• Counter-evidence: None located specific to escitalopram and iron status either way; the gap itself is the main limiting factor.

Regulatory status

Not addressed as an iron-specific warning in the FDA label; bleeding risk generally (including GI bleeding, especially with NSAIDs, aspirin, or anticoagulants) is a labeled class-level warning for SSRIs.

Population evidence

Gomez-Lumbreras et al. 2026, British Journal of Clinical Pharmacology, doi:10.1002/bcp.70432, systematic review and meta-analysis of GI bleeding risk by specific SSRI/SNRI. Drug-specific odds ratios reported (as summarized by Reactions Weekly and GPnotebook secondary coverage of this article): venlafaxine 1.50, citalopram 1.38, fluoxetine 1.38, paroxetine 1.31. Escitalopram was not among the drug-specific estimates retrievable in the sources opened for this review. This makes the bleeding-risk evidence Tier C for escitalopram specifically: a real, drug-stratified finding exists for other class members, not for escitalopram itself.

Mechanism

Named and pharmacologically direct: platelets lack de novo serotonin synthesis and depend on plasma reuptake via the same serotonin transporter escitalopram inhibits therapeutically; chronic depletion of platelet-dense-granule serotonin impairs serotonin-potentiated platelet aggregation. This mechanism applies to escitalopram's own pharmacology, even though the epidemiological bleeding-risk estimate above was not confirmed for escitalopram specifically.

Counter-evidence held on record

Do not recommend iron supplementation on this basis. GI bleeding is a clinical outcome, not iron deficiency in itself (per Hard Rule 2); iron depletion would only follow from chronic or repeated blood loss, which has not been demonstrated for escitalopram specifically. This entry is theoretical and class-extrapolated.

Limits on what this shows

• Why no grade: Dual condition met. Three sources were located that touch copper or a copper-adjacent marker in depression or antidepressant treatment, but none supports even a yellow grade: (1) Styczeń et al. 2016, Biological Trace Element Research, doi:10.1007/s12011-016-0720-5, mixed SSRI/SNRI/TCA/mirtazapine cohort, escitalopram not specifically named; serum copper in depression 0.81±0.27 µg/mL vs controls 0.91±0.39 µg/mL, not statistically significant. (2) Kaya et al. 2012, Archives of Medical Research 43(4):294-297, mixed-antidepressant cohort (venlafaxine specifically named for a subset, escitalopram not confirmed); serum ceruloplasmin elevated in depression at baseline versus controls (p<0.001) but unchanged after 8 weeks of antidepressant treatment (p=0.260). Both are Tier C at best for escitalopram and both are null findings, so neither supports a yellow grade under this protocol's rule that null Tier C evidence does not count as supporting evidence. (3) Mlyniec K, Ostachowicz B, Krakowska A, Reczynski W, Opoka W, Nowak G. 2014. "Chronic but not acute antidepressant treatment alters serum zinc/copper ratio under pathological/zinc-deficient conditions in mice." Journal of Physiology and Pharmacology. PMID 25371526. An animal (mouse) study that surfaced specifically under a PubMed search combining "escitalopram" and "copper," suggesting escitalopram may be one of the antidepressants named in its text, but its abstract could not be opened and read in this review (detailed under Channels tried), so per this protocol's rule against citing a source that was not opened, it is disclosed as an identified lead, not used to support a grade.

Channels tried

A PubMed search-listing query for "escitalopram copper" was successfully opened in this repair pass and returned the Mlyniec et al. 2014 record above (source 3) plus two unrelated hits; the Mlyniec article's own PubMed page then returned only page metadata with no abstract body on repeated attempts, consistent with a script-gated interstitial, matching the earlier CAPTCHA-style block reported for this category previously. The publisher's own site (jpp.krakow.pl) returned an HTTP 403 on a direct fetch. Crossref bibliographic queries under several author-name and title phrasings did not surface a matching DOI or abstract for this specific paper, though one unrelated Crossref query in this review did succeed, and a second, for a different case report used in the Oxygen delivery/utilization entry above, also succeeded after a wait, showing the block is inconsistent rather than absolute. Direct queries to the OpenAlex API, the Semantic Scholar Graph API, the Europe PMC REST API, and NCBI's eutils service were rejected at this session's own network egress policy layer; the proxy's status endpoint confirms these as organizational policy denials (HTTP 403 "gateway answered 403 to CONNECT, policy denial") on api.openalex.org, api.semanticscholar.org, www.ebi.ac.uk, and eutils.ncbi.nlm.nih.gov specifically, not ordinary upstream rate limiting, meaning a future revision will need those hosts allowlisted rather than simply retried. General web search across multiple phrasings, plus two general search engines and a PMC search page, were also tried for corroborating or full-text access to the Mlyniec paper and were blocked by robots.txt or connection failures. This is a genuine, thoroughly attempted gap; a future revision should specifically pursue PMID 25371526 once one of the blocked channels above becomes reachable, since a real, escitalopram-associated candidate source has now been identified even though it could not be read in this pass.

Limits on what this shows

• Key negative/null findings: Shen et al. explicitly report that "the metabolic function of gut microbiota after treatment was still different from that of the control group", taxonomic/diversity normalization did not translate into full functional normalization. This is a genuine partial-null finding within the same study.
• At-risk subgroups: Not established; the study population was a single-site MDD cohort and generalizability across ages, sexes, or comorbidities has not been tested.
• Counter-evidence: No directly contradicting study located. The principal limitation is the absence of independent replication, not a competing dataset.

Regulatory status

Not addressed in the FDA label.

Population evidence

Shen et al. 2021, Scientific Reports, doi:10.1038/s41598-021-94481-1. Longitudinal three-group design: 30 MDD patients (escitalopram monotherapy exclusively, up to 20 mg/day) and 30 healthy controls, with a post-treatment follow-up arm after 4-6 weeks (until Hamilton depression scale reduction ≥50%). Alpha diversity was significantly higher in untreated MDD patients than in controls; after treatment, alpha diversity was no longer significantly different from controls. Firmicutes/Bacteroidetes ratio shifted with treatment; Christensenellaceae, Eubacterium, and Fusobacterium abundance increased after treatment; Lactobacillus abundance decreased after treatment.

Mechanism

Not fully elucidated in this study. Broader, class-level gut-brain-axis literature (not independently verified drug-by-drug in this review) proposes serotonergic signaling and direct antimicrobial-like activity of SSRIs against some gut bacteria in vitro; disclosed here explicitly as class-level context, not as escitalopram-specific confirmation beyond the Shen et al. findings above.

Counter-evidence held on record

Present as "one escitalopram-specific study found partial gut-microbiome normalization with treatment, not yet independently replicated," never as an established, generalizable drug effect. No probiotic or supplement recommendation follows from this single dataset.

Limits on what this shows

• Key negative/null findings: No effect was reported at concentrations approaching clinical plasma levels; no human ATP or cellular-bioenergetics data for escitalopram were located.
• At-risk subgroups: None established in humans.
• Counter-evidence: None specific to ATP measurement; see Mitochondrial burden entry for the same general counter-context.

Regulatory status

Not addressed in the FDA label.

Population evidence

Hroudová J, Fišar Z, Łupták M. 2023. Antioxidants 12(6):1208. At 50 µmol/L, complex I-linked ATP kinetics were significantly inhibited to 81.6% of control; complex II-linked ATP kinetics were inhibited to 81.5% of control at the same concentration. Same in vitro isolated pig brain mitochondria system as the Mitochondrial burden entry.

Mechanism

Downstream of the same electron-transport-chain inhibition described under Mitochondrial burden; not an independently confirmed separate mechanism.

Counter-evidence held on record

Do not count this alongside Mitochondrial burden as two independent confirmations of drug-related bioenergetic harm; both entries rest on the same single in vitro experiment at the same supraphysiologic concentrations.

Limits on what this shows

• Key negative/null findings: No population-level, cohort, or pharmacovigilance-database study of escitalopram and hemoglobin, hematocrit, or red-cell parameters was located despite a multi-channel search (see the Copper entry below and the access note in Sources for the channels attempted in this review). This remains a single idiosyncratic case, and causal attribution is confounded by the atypical intravenous self-administration route, which is not how the drug is intended, labeled, or normally used.
• At-risk subgroups: Not established beyond this single patient. The exposure itself, self-administered intravenous use of an oral-only product, is itself a marker of misuse or possible self-harm behavior rather than a subgroup defined by standard prescribed use.
• Counter-evidence: No corroborating or contradicting case series was located; the source article itself describes this as the first reported instance of this specific association, so it should not be read as an established or population-relevant risk of standard oral escitalopram therapy.

Regulatory status

Not addressed in the FDA label's Warnings and Precautions for the labeled oral tablet/solution product; the case itself involved a non-labeled intravenous route of administration, not the labeled oral formulation covered by the Pharmacokinetic basis panel above.

Population evidence

Hussain M, Boyer K, Ponnapalli A, Awuah D, Khaneki S, Deliwala S, Bachuwa G. 2022. European Journal of Case Reports in Internal Medicine. doi:10.12890/2022_003228, PMID 35402326. Single case report: a patient self-administered escitalopram intravenously and developed hypoproliferative pancytopenia, bone marrow failure affecting red cells, white cells, and platelets together. The authors describe this as the first literature documentation of escitalopram-associated aplastic anaemia specifically. The patient recovered following corticosteroids and supportive care.

Mechanism

Not established. The case report's own abstract notes that escitalopram has rarely been associated with drug-induced thrombocytopenia in prior literature; those underlying prior reports were not independently opened or verified in this review and are relayed here only as background context supplied by this article's authors, not as independently confirmed citations.

Counter-evidence held on record

This finding arose from non-labeled intravenous self-administration of an oral medication, a misuse or self-harm context, not standard oral therapeutic dosing. Do not present this as an expected risk of taking escitalopram as prescribed. No routine complete blood count or bone-marrow monitoring is supported by this single case for patients on standard oral therapy; unusual bleeding, bruising, infection, pallor, or fatigue in any patient on escitalopram still warrants ordinary clinical evaluation, not specifically because of this entry.